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Immunosenescence is a progressive deterioration of the immune system with aging. 
It affects both innate and adaptive immunity limiting the response to pathogens and 
to vaccines. As chronic cytomegalovirus (CMV) infection is probably one of the major 
driving forces of immunosenescence, and its persistent infection results in functional 
and phenotypic changes to the T-cell repertoire, the aim of this study was to analyze 
the effect of CMV-seropositivity and aging on the expression of CD300a and CD161 
inhibitory receptors, along with the expression of CD57 marker on CD4+, CD8+, 
CD8+CD56+ (NKT-Like) and CD4−CD8− (DN) T-cell subsets. Our results showed that, 
regardless of the T-cell subset, CD57−CD161−CD300a+ T-cells expand with age in CMV-
seropositive individuals, whereas CD57−CD161+CD300a+ T-cells decrease. Similarly, 
CD57+CD161−CD300a+ T-cells expand with age in CMV-seropositive individuals in all 
subsets except in DN cells and CD57−CD161+CD300a− T-cells decrease in all T-cell sub-
sets except in CD4+ T-cells. Besides, in young individuals, CMV latent infection associ-
ates with the expansion of CD57+CD161−CD300a+CD4+, CD57−CD161−CD300a+CD4+, 
CD57+CD161−CD300a+CD8+, CD57−CD161−CD300a+CD8+, CD57+CD161−CD300a+ 
NKT-like, and CD57+CD161−CD300a+DN T-cells. Moreover, in young individuals, CD161 
expression on T-cells is not affected by CMV infection. Changes of CD161 expres-
sion were only associated with age in the context of CMV latent infection. Besides, 
CD300a+CD57+CD161+ and CD300a−CD57+CD161+ phenotypes were not found in any 
of the T-cell subsets studied except in the DN subpopulation, indicating that in the majority 
of T-cells, CD161 and CD57 do not co-express. Thus, our results show that CMV latent 
infection impact on the immune system depends on the age of the individual, highlighting 
the importance of including CMV serology in any study regarding immunosenescence.
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inTrODUcTiOn
The human CD300 family has seven members, including the inhibitory receptor CD300a, which has 
been proposed as a possible biomarker for diagnosis and therapeutic target in several pathological 
situations (i.e., infectious diseases and cancer) (1–4). Human CD300a receptor is expressed on the 
surface of T (5, 6) and natural killer (NK) cells (7, 8). On human NK cells, the interaction between 
Table 1 | Demographics of studied individuals (n = 64).
cMV age (years) no. group name
Negative 18–35 22 Young CMV-seronegative
Positive 18–35 15 Young CMV-seropositive
Positive 40–65 13 Middle age CMV-serpositive
Positive >70 14 Old CMV-serpositive
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CD300a and its ligand reduces their cytotoxic function (8). In 
T and B cells, the primary function of CD300a is to limit antigen 
receptor-mediated positive signaling (9). However, on CD8+ 
T-cells, CD300a expression has been shown to associate with bet-
ter cytotoxic function (10) and CD300a+CD4+ T-cells are associ-
ated with polyfunctionality and, upon stimula tion, upregulate the 
transcription factor Eomesodermin (Eomes) (6, 11).
CD161 marker is a C-type lectin that was originally described 
in NK  cells (12, 13). Nevertheless, CD161 is also expressed by 
T-cells including CD4+, CD8+ (12), and γδ T-cells (14). Within 
the CD4+ subset, CD161 expression has been associated with 
IL-17 production. Indeed, Th17  cells can be originated from 
the CD161+CD4+ but not from their CD161−CD4+ counterpart 
(15). Of note, other IL-17-producing T-cells, such as CD8+ and 
CD4−CD8− double-negative T-cells are as well CD161+ (16). 
Furthermore, it has been shown that CD161 expression on T-cells 
characterizes a transcriptional and functional T-cell phenotype 
that is TCR- and cell lineage-independent (17). All CD161+ 
T-cell subsets shared a transcriptional signature and responded 
in a TCR-independent (innate-like) way to cytokine stimulation 
(IL-12 plus IL-18). However, CD161 had no regulatory effect 
on this response. Instead, CD161 has been shown to function 
as a costimulatory receptor in the context of TCR stimulation 
(18, 19). While the role of CD161 receptor on NK cells is agreed 
to be inhibitory (12, 20, 21), on T-cells, there is lack of consensus, 
as there is evidence of both costimulatory (20, 22) and inhibitory 
(18, 19) effects.
During aging, both innate and adaptive immunity are affected. 
Age-related changes have been described in several immune 
cell types including T-cells, NK cells, B-cells, macrophages, etc. 
Among those changes, the alterations in the number, phenotype, 
and functional capacity of immune cells have been associated with 
higher susceptibility to infectious diseases that ultimately lead to 
increased risk of fragility and death in those individuals (23–26). 
This age-associated deterioration of the immune system has been 
termed “immunosenescence.” However, immunosenescence is 
not exclusively due to chronological aging of the individual and 
there are situations involving chronic stimulation of the immune 
system, such as viral infections, in which an “immunosenescence 
accelerated” or “early immunosenescence” is observed (27–30). In 
humans, infection by a common virus, cytomegalovirus (HCMV) 
has been shown to have profound impact on the T-cell compart-
ment both on CD8+ and CD4+ T-cells (31, 32). HCMV persists 
after primary infection and is continuously controlled by the 
immune system (33, 34). Human herpes viruses, like CMV, have 
generally a benign/symbiotic relationship with the host (35–38). 
However, this benign relationship between herpesviruses and 
its hosts is altered with age. Indeed, CMV latent infection has 
been related to early immunosenescence (32, 39, 40). Particularly, 
CMV-seropositivity is associated with an increased risk of death 
and cardiovascular diseases (41–43) and is a contributor to the 
development of an "Immune Risk Phenotype" (IRP). This IRP is 
associated with early mortality in the elderly (44–46). Therefore, 
HCMV is considered one of the most relevant contributors to 
immunosenescence.
Thus, both HCMV infection and age contribute to the 
process of immunosenescence inducing changes on the T-cells. 
Understanding the mechanisms leading to immunosenescence 
and finding new biomarkers could open the possibility of novel 
therapies for the treatment of age-related diseases. In that regard, 
here, we study the effect of CMV latent infection and age on the 
expression of CD161 and CD300a receptors on CD4+, CD8+, 
CD8+CD56+ (NKT-like), and CD4−CD8− (DN) T-cell subsets 
and their relation with the polyfunctionality marker CD57, which 
is a hallmark of CMV infection and aging in T-cells (37, 38).
MaTerials anD MeThODs
subjects
We studied 64 healthy individuals stratified according to age 
and CMV serostatus (Table 1). Individuals in the old group and 
middle age group were all CMV-seropositive, as we were not able 
to recruit enough CMV-seronegative individuals due to the high 
prevalence of CMV seropositivity in Spain, which is about 80% 
in individuals over the age of 40 years (47) and reaches about 99% 
in individuals over 65 years in Andalusia (Southern Spain) where 
the samples were collected.
All subjects studied met the following exclusion criteria: 
absence of diabetes, cancer, severe renal failure, severe liver 
disease, endocrine disorders, autoimmune diseases, or acute 
infectious disease; they were not consuming drugs whose activity 
is known to modify the functions of the immune system. Ethical 
statement was approved by the Ethics Committee of the Reina 
Sofia University Hospital and all study participants provided 
informed written consent.
cMV serology
CMV-specific IgG and IgM was determined in sera by using 
automated enzyme-linked immunosorbent assay (ELISA) (DRG 
International, Mountainside, NY, USA).
Flow cytometry and Data analysis
Peripheral blood from each subject was collected in lithium 
heparin tubes, followed by PBMCs isolation by density gradient 
centrifugation using Ficoll Histopage-1077 (Sigma-Aldrich, St. 
Louis, MO, USA). After isolation, PBMCs were cryopreserved 
until experiments were performed.
Cell thawing was carried out in RPMI 1640 (Sigma-Aldrich) 
with 10% FBS (Gibco, Life Technologies CA, USA) and cells 
were placed in a 96-well plate at 2 × 106 cells/ml concentration 
(250  µl final volume). Subsequently, cells were washed twice 
with PBS (4°C) and stained for the following antibodies: anti-
CD3 PerCP (clone: BW 264/56, MiltenyiBiotec), anti-CD56 
phosphatidylethanolamine (PE)-Cy7 (clone: B159, BD Pharmin-
gen), anti-CD57 VioBlue (clone: TB03, MiltenyiBiotec), anti- 
CD300a PE (clone: E59.126, Beckman Coulter), anti-CD4 FITC 
FigUre 1 | Expression of CD57, CD161, and CD300a in T-cells. CD57, CD161, and CD300a co-expression patterns (pie charts) in CD4+, CD8+, NKT-like, and DN 
T-cells from healthy individuals (n = 64), stratified by age and CMV serostatus. Results were considered significant at *p < 0.05, **p < 0.01, and ***p < 0.001.
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(clone: M-T466, MiltenyiBiotec), anti-CD8 APC-Cy7 (clone: SK1, 
BD Biosciences), and anti-CD161 APC (clone: DX12, BD Phar-
mingen). All antibodies were titrated before use.
Samples were acquired with a nine parameters MACsQuant 
instrument (Miltenyi Biotech, BergischGladbach, Germany) and 
analyzed with FlowJo v X 10.0.7 software (TreeStar, Portland, OR, 
USA). First, lymphocytes were gated according to their size and 
granularity (FSC vs SSC), then forward scatter height versus for-
ward scatter area to remove doublets. Within that gate (singlets), 
CD3+ T-cells were gated, followed by identification of the differ-
ent T-cell subsets by confronting CD4 vs CD8. NKT-like cells 
(CD8+CD56+) were then gated from CD8+ T-cells (Figure S1A in 
Supplementary Material). The average number of events acquired 
for each subset was: 71161 cells for CD4+ subset, 32498 cells for 
CD8+, 5708 cells for NKT-like, and 5511 cells for DN. Individual 
gates (set based on fluorescence minus one controls) for CD57+, 
CD161+, and CD300+ cells were gated on each of these popula-
tions (Figure S1B in Supplementary Material). FlowJo’s Boolean 
gating options were performed to analyze the co-expression of 
CD57, CD161, and CD300a markers.
statistical analysis
Data were inspected for normal distribution using the 
Shapiro–Wilk test. No normality was found. According to this, 
FigUre 2 | CD57, CD300, and CD161 expression on CD4+ T-cells. (a) Total expression (percentage) of CD57, CD161, and CD300a on CD4+ T-cells from young 
CMV-seronegative (n = 22), young CMV-seropositive (n = 15), middle age CMV-seropositive (n = 13), and old CMV-seropositive donors (n = 14). (b) Co-expression 
of CD57, CD161, and CD300a on CD4+ T-cells. Graphs show CD4+ T-cell phenotypes in which we found statistical differences among the four groups studied. 
Vertical blacklines indicate interquartile ranges, ranging from the 25th to the 75th percentile. The median values are indicated by a horizontal black line. Results were 
considered significant at *p < 0.05, **p < 0.01, and ***p < 0.001.
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Kruskal–Wallis H test (non-parametric test) with correction for 
multiple comparisons was used for direct comparison of the 
four groups. Those variables in which we found a statistical sig-
nificant difference were then analyzed using the Mann–Whitney 
U non-parametric test for comparing data among the specific 
sample pairs. All statistical tests were performed with PASW 
Statis tics v18. For scatter graphs, GraphPad Prism (version 5.0) 
was used. All graphs reflect only the Mann–Whitney derived 
p-values. To compare the pie charts, we used SPICE’s permutation 
analysis (Mario Roederer, ImmunoTechnology Section, Vaccine 
FigUre 3 | Continued
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FigUre 3 | Continued  
CD57, CD300, and CD161 expression on CD8+ T-cells. (a) Total expression (percentage) of CD57, CD161, and CD300a markers on CD8+ T-cells from young 
CMV-seronegative (n = 22), young CMV-seropositive (n = 15), middle age CMV-seropositive (n = 13), and old CMV-seropositive donors (n = 14). (b) Co-expression 
of CD57, CD161, and CD300a on CD8+ T-cells. Graphs show the phenotype combinations CD8+ T-cells in which we found statistical differences among the four 
groups studied. Vertical blacklines indicate interquartile ranges, ranging from the 25th to the 75th percentile. The median values are indicated by a horizontal black 
line. Results were considered significant at *p < 0.05, **p < 0.01, and ***p < 0.001.
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Research Centre, NIH, Bethesda, MD, USA) (48), which asks 
how often given the samples that comprise the two pies charts, 
the difference observed would happen simply by chance (10,000 
permutations).
resUlTs
cD57, cD161, and cD300a expression on 
T-cells
Multicolor flow cytometry was used to analyze the expression of 
CD57, CD161, and CD300a markers on CD4+, CD8+, NKT-like, 
and DN T-cell subpopulations from healthy individuals stratified 
by age and CMV-serostatus (Table 1).
FlowJo’s Boolean analysis of CD57, CD161, and CD300a 
expression generated eight different possible phenotype combi-
nations per T-cell subset. However, not all the possible combina-
tions were biologically meaningful. Phenotype profiles for each 
subset were obtained using SPICE software (Figure 1).
CD4+ T-Cells
Analysis of CD4+ T-cell subset showed that CD57+CD4+ and 
CD300a+CD4+ T-cells increased with age in CMV-seropositive 
individuals and with CMV infection in young individuals 
(Figure  2A). In contrast, CD161+CD4+ T-cells percentage was 
decreased with age (Figure 2A).
Out of the eight possible Boolean phenotype combinations, we 
only found five within the CD4+ T-cell subset, as the percentages 
of cells with CD57+CD161+CD300a+, CD57+CD161+CD300a− 
and CD57+CD161−CD300a− phenotypes were noticeably low or 
null in all subjects studied (Figure 1).
The majority of CD4+ T-cells in young and middle-age 
individuals did not express any of the markers studied (CD57− 
CD161−CD300a−). However, in the elderly, more than 50% of 
the cells were CD300a+ (55.67%, IQR 46.62–66.99) alone or in 
combination with CD161 or CD57 (Figures 1 and 2A, Table S1 
in Supplementary Material). Our data as well showed that the 
percentage of triple negative (CD57−CD161−CD300a−) CD4+ 
T-cells was decreased by CMV infection in young individuals. The 
progressive reduction of CD57−CD161−CD300a− CD4+ T-cells 
by CMV infection and age corresponded with an increase of 
CD57−CD161−CD300a+ and CD57+CD161−CD300+ phenotypes 
(Figure 2B). Of note, CD57+CD4+ T-cells were only present in 
CMV-seropositive individuals and always co-expressing CD300a 
(Figures 1 and 2B).
On the other hand, our analysis showed that CD161 is 
never co-expressed with CD57 in any of the groups studied 
(Figure 1). CD57−CD161+CD300a− and CD57−CD161+CD300a+ 
CD4+ T-cells decreased with age in CMV-seropositive individuals, 
being the percentage of CD57−CD161+CD300a− cells very low 
or null in the elderly (Figures 1 and 2B).
Furthermore, the phenotype profiles of CD4+ T-cells changed 
with age in CMV-seropositive individuals, but not with CMV 
infection alone (pie charts representing the three makers’ 
combinations, Figure 1). This shift of phenotype is mainly due 
to an accumulation with age of the CD57−CD161−CD300a+ and 
CD57+CD161−CD300a+ phenotypes in the CMV-seropositive 
individuals.
CD8+ T-Cells
Data from CD8+ T-cell subset showed that CD57+CD8+ T-cells 
increased with CMV infection alone and in combination with 
age. While, CD300a+CD8+ T-cells accumulate with age in CMV-
seropositive individuals and CD161+CD8+ T-cells decreased 
progressively being very low or null in the elderly (Figures  1 
and 3A).
The percentages of CD57+CD161+CD300a+ and CD57+CD161+ 
CD300a− CD8+ T-cells were noticeably low or null in all subjects 
studied. The majority of CD57+CD8+ T-cells were positive for 
CD300a and negative for CD161 (Figure 1). However, in contrast 
to CD4+ T-cells, in the CD8+ subset, we found a small fraction of 
cells with CD57+CD161−CD300a− phenotype (pie slice orange, 
Figure 1), not affected by age.
In young and middle age individuals, 60–70% of the CD8+ 
T-cells were mainly CD57−CD161−CD300a− (Table S1 in 
Supplementary Material). However, in the elderly, only 17% (IQR 
7.20–29.30) of CD8+ T-cells did not express any of the markers 
(Figure  3B; Table S1 in Supplementary Material). This drastic 
reduction observed in the elderly is due to the expansion of 
CD300a+ cells with or without CD57 (yellow and pink pie slices, 
Figure 1). In young individuals, CD57−CD161−CD300a− CD8+ 
T-cells decreased with CMV infection (Figure  3B) due to the 
expansion of CD57+CD161−CD300a+ cells (yellow pie slice, 
Figures 1 and 3B).
Additionally, we observed that in young and middle age 
individuals, CD161+CD8+ T-cells were CD300a+ or CD300a−, 
whereas in the elderly, the few CD161+ cells observed were all 
CD300a+ (pie slices red and violet, Figure 1).
The phenotype profiles (pie charts, Figure 1) of CD8+ T-cells 
changed noticeably with age in CMV-seropositive individuals, 
but not with CMV infection alone (Figure 1).
CD8+CD56+ T-Cells (NKT-Like Cells)
The expression of CD57, CD161, and CD300a markers on 
NKT-like cells was not affected by CMV infection alone. 
However,  CD57+ and CD300a+ NKT-like cells increased with 
age in CMV-seropositive individuals (Figure 4A), while CD161+ 
NKT-like cells decreased (Figure 4A).
FigUre 4 | Continued
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FigUre 4 | Continued  
CD57, CD300, and CD161 expression on NTK-like cells. (a) Total expression (percentage) of CD57, CD161, and CD300a markers on NKT-like cells from young 
CMV-seronegative (n = 22), young CMV-seropositive (n = 15), middle age CMV-seropositive (n = 13), and old CMV-seropositive donors (n = 14). (b) Co-expression 
of CD57, CD161, and CD300a on NKT-Like cells. Graphs show the markers combinations in which we found statistical differences among the four groups studied. 
Vertical black lines indicate interquartile ranges, ranging from the 25th to the 75th percentile. The median values are indicated by a horizontal black line. Results  
were considered significant at *p < 0.05, **p < 0.01, and ***p < 0.001.
8
Hassouneh et al. T-Cells, CMV, and Aging
Frontiers in Immunology | www.frontiersin.org June 2017 | Volume 8 | Article 649
CD57+CD161+CD300a+ and CD57+CD161+CD300a− NKT-
like cells were very low or null. Thus, in our hands, as CD4+ 
and CD8+ subsets, NKT-like cells did not co-express CD57 and 
CD161 (pie slice orange, Figure 1). The majority of CD57+ NKT-
like cells were also CD300a+. However, we observed a small frac-
tion of NKT-like cells with a CD57+CD161−CD300a− phenotype, 
not affected by CMV infection and age (Figure 1). Of note, in 
the elderly, 47.35% (IQR 36.70–65.10) of the NKT-like cells were 
CD57+CD161−CD300a+ (yellow pie slice, Figure 1). The propor-
tion of this phenotype is significantly lower (p < 0.001) in the rest 
of the T-cell subsets studied, particularly in the CD4+ T-cells in 
which this phenotype frequency is quite low even in the elderly 
(Figure 1).
In the NKT-like subset, 65–95% of the cells expressed at least 
one of the markers studied, being the fraction of triple nega-
tive cells (CD57−CD161−CD300a−) very low in old individuals 
(5.58%, IQR 1.77–10.20) (Figures 1 and 4B), due to the expan-
sion of CD57−CD161−CD300a+ and CD57+CD161−CD300a+ 
phenotypes (pie slices pink and yellow, Figure  1). Noticeably, 
CD57+CD161−CD300a+ cells were also increased in young CMV-
seropositive individuals compared with CMV-seronegative 
(Figure 4B).
NKT-like CD161+ phenotypes (CD57−CD161+CD300a− and 
CD57−CD161+CD300a+) decreased with age in CMV-seropositive 
individuals, but not with CMV infection alone (Figures 1 and 4B). 
Remarkably, the percentage of CD57−CD161+CD300a− NKT-
like cells was very low or null in middle age and old individuals 
(Figure 4B; Table S1 in Supplementary Material).
As in the CD4+ and CD8+ main populations, the phenotype 
profiles of NKT-like cells were not affected by CMV infection 
alone (Figure 1).
CD4−CD8− T-Cells (DN T-Cells)
Data from DN T-cells (majorly γδ T-cells) flow analysis showed a 
similar percentage of CD57+ DN T-cells among the three CMV-
seropositive groups (young, middle age, and old) (Figure  5A). 
While, CD161+ DN T-cell decreased gradually with age in CMV-
seropositive individuals (Figure  5A). Furthermore, CD300a+ 
DN T-cells increased with CMV infection in young individuals 
and further increased in old CMV-seropositive individuals 
(Figure 5A).
As in the other T-cell subsets studied, in DN T-cells the 
percentage of CD57+CD161+CD300a− cells is null (Figure  1). 
However, we observed a small fraction of DN T-cells co-express-
ing the three markers that decreases with age (Figures 1 and 5B).
The majority of DN T-cells in all individuals are CD300a+ with 
or without CD161 or CD57 expression (Figure 1). Our analysis 
showed that the percentage of CD57−CD161−CD300a+ cells 
increased with age in CMV-seropositive individuals, whereas the 
percentage of CD57+CD161−CD300a+ increases with CMV infec-
tion in young individuals and is not affected by age (Figure 5B). 
Of note, our results showed that, similarly to CD57+CD4+ T-cells, 
the majority of CD57+ DN T-cells are as well CD300+ (Figure 1).
Besides, CD161+ DN T-cells were mainly CD57− (only a 
small fraction co-expressed CD161 and CD57). CD57−CD161+ 
CD300a− phenotype decreased with age, being the percentage 
of these cells null in the elderly (pie slice violet, Figures 1 and 
5B). Whereas a reduced percentage of CD57−CD161+CD300a+ 
DN T-cells was still present in old individuals (pie slice red, 
Figures 1 and 5B).
DN T-cell phenotype profiles for the makers studied (pie charts, 
Figure 1) changed with age in CMV-seropositive individuals, but 
not with CMV infection alone.
DiscUssiOn
The combination of age and CMV latent infection has been 
proven to have a profound impact on the immune phenotype 
and function of T-cells, not only on the CD8+ subset but also 
on CD4+, NKT-like, and γδ T-cells. However, age and CMV infec-
tion do not always have similar effects and it can vary depending 
on the cell type.
Here, we analyzed, in different T-cell subsets, how age and 
CMV infection alter the expression of the inhibitory receptors 
CD300a and CD161 and their relation with the marker CD57, 
which has been shown to be a polyfunctionality maker of CD4+, 
CD8+, and NKT-like T-cells (37, 38, 49). We are aware that due 
to the high prevalence of CMV in our geographic area (see 
Materials and Methods), a limitation of our study is the lack of 
CMV-seronegative individuals of older ages (middle age and old 
groups). Thus, we can only assess the effect of aging in the context 
of CMV latent infection. Nevertheless, we were able to investigate 
the effect of CMV infection alone in young individuals.
Our analysis showed that in all T-cell subsets studied, CD57 
and CD300a increase with age in CMV-seropositive individuals. 
Specifically, with CMV infection (young individuals), CD57 is 
increased only in CD4+ and CD8+ T-cells and CD300a in CD4+ 
and DN subsets. No effect of CMV alone was observed on NKT-
like cells. Of note, CD57+CD4+ T-cells are always CD300a+ and 
were only found in CMV-seropositive individuals. In the rest of 
subsets (CD8+, NKT-like and DN), although not all, the majority 
of CD57+ T-cells were CD300a+ as well, regardless of the age and 
CMV serostatus.
The expression of CD300a by several immune cell types 
has been associated with different pathologies, suggesting that, 
although the significance of CD300a on T-cell function is not 
completely clear, CD300a could be used as a biomarker and a 
target for new therapies [for review, see Ref. (50)].
FigUre 5 | Continued
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FigUre 5 | Continued  
CD57, CD300, and CD161 expression on CD4−CD8− T-cells (DN). (a) Total expression (percentage) of CD57, CD161, and CD300a markers on DN T-cells  
from young CMV-seronegative (n = 22), young CMV-seropositive (n = 15), middle age CMV-seropositive (n = 13), and old CMV-seropositive donors (n = 14).  
(b) Coexpression of CD57, CD161, and CD300a on DN T-cells. Graphs show DN T-cells phenotypes in which we found statistical differences among the four 
groups studied. Vertical black lines indicate interquartile ranges, ranging from the 25th to the 75th percentile. The median values are indicated by a horizontal  
black line. Results were considered significant at *p < 0.05, **p < 0.01, and ***p < 0.001.
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CD300a ligands, phosphatidylserine (PS), and phosphatidyle-
thanolamine (PE) are associated with virus evasion. Indeed, anti-
PS antibody has been shown to be a potential treatment for CMV 
and Pichinde virus infections (51). Additionally, HIV-specific 
CD8+ T-cell mRNA levels of CD300a receptor have been shown to 
correlate with the expression of BATF transcription factor, which 
is highly expressed in exhausted cells. BTAF inhibits cell function 
by inducing the expression of inhibitory receptors such as CD300a 
(52). Viral envelope expression of PS and PE has been shown to be 
an evasion mechanism called “apoptotic mimicry” (53). However, 
CD300a binding to viruses expressing PS and PE in their envelopes 
seams to inhibit the virus endocytosis, most probably hampering 
the virus infection. All these data supports that CD300a has an 
inhibitory role and it is important for viral infections.
However, in CD8+ T-cells, CD300a expression associ-
ates with higher cytotoxicity and CD300a+CD8+ T-cells are 
increased in pregnant women with chronic choriamnionitis 
(10). Additionally, CD300a has been shown to be a polyfunc-
tionality marker in CD4+ T-cells and CD300a+CD4+ T-cells 
upregulate Eomes transcription factor after stimulation (11). 
Furthermore, our group has recently shown that CD57+CD4+ 
T-cells are polyfunctional and express high levels of T-bet and 
Eomes transcription factors upon superantigen stimulation (38). 
Moreover, CD57+CD8+ T-cells correlate with polyfunctionality 
of CD8+ T-cells and are expanded in young CMV-seropositive 
individuals (37).
Whether CD300a+CD57− and CD300a+CD57+ T-cells display 
any differences regarding polyfunctionality and if there are dif-
ferences in regards of T-bet and Eomes expression is currently 
under investigation in our laboratory. This analysis will allow 
us to establish if CD300a is a polyfunctional marker of T-cells 
per se, or only if co-expressed with CD57. In our hands CD57+ 
T-cells co-expressing CD300a expand with CMV infection 
(in young individuals), highlighting a relevant role for both mak-
ers in the control of CMV virus by T-cells. On the other hand, 
CD161 receptor was hardly co-expressed with CD57 in any of 
the T-cell subsets studied. Particularly, co-expression of CD161 
and CD57 was not observed in the elderly regardless of the T-cell 
subset. Furthermore, the total expression of CD161, contrarily 
to CD57 and CD300a, decreases with age in CMV-seropositive 
individuals and is not affected by CMV infection alone in young 
individuals. Our results support previous results from healthy 
children in which the expression of CD161 on T and NK cells was 
not affected by CMV serostatus (54). However, Almehmadi et al. 
suggest that NKT-like cells not expressing CD161 are increased 
in CMV-seropositive individuals. This discrepancy with our data 
can be explained by the fact that Almehmadi’s cohort does not 
stratify the individuals by age (23–60 years), only by CMV status. 
Additionally, their definition of NKT-like cells differs from ours 
as it is based only on CD3 and CD56 expression, not including 
CD8 [for review of NKT-like cells nomenclatures, see Ref. (55)]. 
In our previous work, regarding NKT-like cell number and func-
tionality in the context of CMV infection and age, we show that 
the percentage of NKT-like cells is not affected by CMV infection 
in young CMV individuals, but rather with the combined effect 
of both age and CMV latent infection (49). Similarly, the loss of 
CD161 by T-cells does not associate with CMV alone, but with 
age in the context of CMV latent infection. Indeed, the expres-
sion of CD161 in CMV-specific cytotoxic T lymphocytes is very 
low (56).
Besides, acute and chronic GVHD correlates with decreased 
levels of circulating CD161+CD4+ and CD161++CD8+ T-cells (57). 
Moreover, in rheumatoid arthritis patients, it has been shown an 
increase of CD161+CD4+ T-cells, but a decrease of CD161+ DN 
T-cells that was associated with disease activity and inflammation 
(58, 59). As we mentioned before, T-cells-expressing CD161 are 
IL-17 producers. In our cohort, the percentages of CD161+ T-cells 
are very low or null in old CMV-seropositive individuals regard-
less of the T-cell type. This could translate in a diminished Th17 
response in the elderly.
Contrarily to what we observe in T-cells, our previous work on 
NK cells showed a decreased expression of CD161 on CD56dim 
NK cells associated with CMV seropositivity (60).
The data presented here together with our previous results 
highlight the importance of taking into account both age and CMV 
serostatus in any clinical study regarding the analysis of T-cells, 
as CMV latent infection has a differential effect with age on T-cell 
subsets. Additionally, our data support the potential use of CD57, 
CD300a, and CD161 as biomarkers of immunosenescence and as 
possible targets for novel therapies. The clinical implications of 
the changes found in the expression of these makers should be 
further investigated.
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